A phase I study of Anti-CD123 CAR-T cell therapy

Trial Profile

A phase I study of Anti-CD123 CAR-T cell therapy

Phase of Trial: Phase I

Latest Information Update: 15 Dec 2016

At a glance

  • Drugs Anti-CD123 CAR-T cells-Sorrento Therapeutics (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 15 Dec 2016 New trial record
    • 01 Dec 2016 According to a Sorrento Therapeutics media release, the company plans to file an Investigational New Drug Application (IND) in the first half of 2017 and trial initiation is expected in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top